Novel Rx
A clinical trial in early axial spondyloarthritis (axSpA) demonstrated sustained inactive disease status in over 60% of patients. In axSpA patients with less than 1 year of disease symptoms, male sex…
It is almost four years since EULAR published its definition of difficult-to-treat (D2T) rheumatoid arthritis (RA) (1). This marked a formal recognition of the group of patients who, despite the…
11 months 2 weeks ago
Is Izokibep the new kid on the block in PsA?
➡️ IL-17A inhibitor
➡️ Complete resolution of enthesitis at 16w
➡️ Overall good safety data
LBA0005 #EULAR2024 @RheumNow https://t.co/8htPOz9YCG
11 months 2 weeks ago
EULAR
OP0041 (2024)
COMPARISON OF b/tsDMARDs ABOUT NON-INFLAMMATORY PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS–ANSWER LONGITUDINAL COHORT STUDY. 25% RA have significant non-inflammatory pain https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
11 months 2 weeks ago
EULAR
OP0092 (2024)
INFECTIONS IN PATIENTS WITH RA TREATED WITH JAKi COMPARED TO bDMARDs: AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY) TNF,OMA,JAK 7-10/100 pt.yr no signif diff except for zoster >30,000pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024
11 months 2 weeks ago
RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH COHORT STUDY- despite having minimal sun 25% increase NMSC TNFis vs other bDMARDs - skin checks ! @RheumNow #EULAR2024
Poster Hall